Eisai Inc.

This study tested a drug called lecanemab (BAN2401) in 856 people with early Alzheimer's disease (mild cognitive impairment or mild dementia). Participants received different doses of the drug or a placebo every 2 or 4 weeks for 18 months. The goal was to see if the drug could sl…

This study tested a combination of two drugs, lenvatinib and pembrolizumab, against standard chemotherapy for advanced endometrial cancer that had worsened after initial treatment. Over 800 participants were randomly assigned to receive either the new combination or a standard ch…

This study tested an experimental drug called BB-1701 in 56 people with advanced breast cancer that had not responded to prior treatments. The drug targets a protein called HER2 on cancer cells to deliver chemotherapy directly to the tumor. The goal was to find the best dose and …

This study tested a new drug (E7386) combined with an immunotherapy (pembrolizumab) in 89 people with advanced melanoma, colorectal, or liver cancer who had already tried other treatments. The goal was to check safety and see if the combination shrinks tumors. Results help decide…